An interventional study of Sirolimus drug eluting ballooon therapy and Optimal guidelines-directed medical therapies (GDMT) in Coronary Arterial Disease (CAD), Vulnerable Coronary Plaques and Multivessel Coronary Artery Disease, sponsored by Cardiocentro Ticino. Not yet recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-15.
Sponsored by Cardiocentro Ticino · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Acute Coronary Syndrome with a site in Switzerland — 10 open to participants now, 12 under way, 2 of them phase 3. Acute Coronary Syndrome · Switzerland.
Among the 42 studies in Acute Coronary Syndrome with a site in Switzerland, this one is the 28th largest by planned enrollment of the 29 interventional ones that give a count, is one of 6 that started in 2025, is one of 13 with no phase, reaches primary completion later than 6 of the 11 other live ones, and was the 33rd registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.
Browse Acute Coronary Syndrome studies →10 of the 42 studies in Acute Coronary Syndrome with a site in Switzerland are open now. Recruiting first, the newest first:
École Supérieure de Soins Ambulanciers - College of Higher Education in Prehospital Care · Sites in Switzerland
Ages 18+ · Healthy volunteers
Matthias Wilhelm, MD · Sites in Switzerland
Ages 18+
Cardiocentro Ticino · Sites in Switzerland
Ages 18+
Cardiocentro Ticino · Sites in Switzerland
Ages 18+
Hochgebirgsklinik Davos · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 12 · Phase 4 2
First in 1997; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 200 across 868 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 1,200 across the 29 interventional studies, 2,498 across the 13 observational. Of the 26 that completed or were terminated, 8 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 42 have an industry lead sponsor. The 10 most frequent:
Cardiocentro Ticino is the lead sponsor of 13 studies on the registry; 8 are open to participants now.
Cardiocentro Ticino has 3 studies filed under Acute Coronary Syndrome — fewer than ten, so there is no comparison to draw.
7 of the studies in Acute Coronary Syndrome with a site in Switzerland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-01-16 |
| NCT07810686École Supérieure de Soins Ambulanciers - College of Higher Education in Prehospital CareSmartphone AI Assistance for Prehospital ECG Interpretation | 2026-11-30 |
| NCT07597031Matthias Wilhelm, MDFeasibility Study of a Digital Interactive Life-style Platform for Individuals After Rehabilitation | 2027-02-01 |
| NCT04000061University Hospital, Basel, SwitzerlandHeart Failure-USB: Prediction and Progression | 2027-04-04 |
| NCT07091682Biotronik AGSafety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 42 studies in Acute Coronary Syndrome with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this pilot clinical trial is to evaluate the use of the Selution SLR sirolimus-eluting balloon, in addition to guideline-directed medical therapy (GDMT), for the preventive treatment of non-flow-limiting vulnerable coronary lesions, compared to GDMT alone, in adult patients with multivessel coronary artery disease and a recent acute coronary syndrome (within 90 days).
The main research question is:
Does the use of the Selution SLR sirolimus-eluting balloon in combination with GDMT reduce the progression and vulnerability of non-flow-limiting vulnerable coronary plaques?
Participants will undergo
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Potential subjects must fulfill all following inclusion criteria:
Exclusion Criteria:
Patients are not eligible if any of the following applies:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Selution SLR sirolimus-eluting balloon additional to guidelines-directed medical therapy for the preventive treatment of non-flow limiting vulnerable coronary lesions
Device: Sirolimus drug eluting ballooon therapy
Guidelines-directed medical therapy
Drug: Optimal guidelines-directed medical therapies (GDMT)
Non-flow limiting vulnerable coronary plaques are treated using sirolimus drug eluting balloon therapy additional to guidelines directed medical therapy.
Also known as: DEB-GDMT
Optimal guidelines-directed medical therapies (GDMT) to reduce plaque burden and vulnerability for non-flow limiting vulnerable plaques
Absolute change in the IVUS-NIRS derived lipid core burden index (MAXLCBI4mm) between baseline and 6-months follow-up.
Time frame: Between baseline and 6-months follow-up.
QCA parameter (minimal lumen diameter, MLD, mm) before and after intervention and at follow-up angiography.
Minimal lumen diameter (MLD, mm) before the intervention, immediately after the intervention and at follow up angiography.
Time frame: pre procedure, immediately after the procedure and at 6(±30 days) months follow-up.
QCA parameter (maximal diameter stenosis, MaxS,%) before and after intervention and at follow-up angiography.
Maximal diameter stenosis (MaxS,%) before the intervention, immediately after the intervention and at follow up angiography.
Time frame: pre procedure, immediately after the procedure and at 6(±30 days) months follow-up.
QCA parameter (reference vessel diameter, RVD, mm) before and after intervention and at follow-up angiography.
Reference vessel diameter (RVD, mm) before the intervention, immediately after the intervention and at follow up angiography.
Time frame: pre procedure, immediately after the procedure and at 6(±30 days) months follow-up.
QCA parameter (lesion lenght, LL, mm) before and after intervention and at follow-up angiography.
Lesion lenght (LL, mm) before the intervention, immediately after the intervention and at follow up angiography.
Time frame: pre procedure, immediately after the procedure and at 6(±30 days) months follow-up.
QFR parameters before and after the intervention and at follow-up angiography
Quantitative Flow Ration (QFR) parameters before the intervention, immediately after the intervention and at follow-up angiography.
Time frame: pre procedure, immediately after the procedure and at 6(±30days) months follow-up.
IVUS parameter (minimal lumen diameter, MLD, mm) before the intervention, immediately after the intervention and at follow-up angiography.
Minimal lumen diameter (MLD, mm) before the intervention, immediately after the intervention and at follow-up angiography.
Time frame: pre procedure, immediately after the procedure and at 6(±30days) months follow-up.
IVUS parameter (minimal lumen area, MLA, mm2) before the intervention, immediately after the intervention and at follow-up angiography.
Minimal lumen area (MLA, mm2) before the intervention, immediately after the intervention and at follow-up angiography.
Time frame: pre procedure, immediately after the procedure and at 6(±30days) months follow-up.
IVUS parameter (maximal diameter stenosis, MaxS,%) before the intervention, immediately after the intervention and at follow-up angiography.
Maximal diameter stenosis (MaxS, %) before the intervention, immediately after the intervention and at follow-up angiography.
Time frame: pre procedure, immediately after the procedure and at 6(±30days) months follow-up.
IVUS parameter (lumen volume, LV, mm3) before the intervention, immediately after the intervention and at follow-up angiography.
Lumen volume (LV, mm3) before the intervention, immediately after the intervention and at follow-up angiography.
Time frame: pre procedure, immediately after the procedure and at 6(±30days) months follow-up.
IVUS parameter (vessel volume, VV, mm3) before the intervention, immediately after the intervention and at follow-up angiography.
Vessel volume (VV, mm3) before the intervention, immediately after the intervention and at follow-up angiography.
Time frame: pre procedure, immediately after the procedure and at 6(±30days) months follow-up.
IVUS parameter (plaque burden, VV-LV) before the intervention, immediately after the intervention and at follow-up angiography.
Plaque burden (VV-LV) before the intervention, immediately after the intervention and at follow-up angiography.
Time frame: pre procedure, immediately after the procedure and at 6(±30days) months follow-up.
IVUS parameter (late lumen loss, LLL) before the intervention, immediately after the intervention and at follow-up angiography.
Late lumen loss (LLL) before the intervention, immediately after the intervention and at follow-up angiography.
Time frame: pre procedure, immediately after the procedure and at 6(±30days) months follow-up.
IVUS parameter (acute gain) before the intervention and immediately after the percutaneous intervention.
Acute gain before the intervention (T0) and immediately after the percutaneous intervention (Tf).
Time frame: pre procedure and immediately after the procedure.
IVUS parameter (disease progression) after the final result of index PCI (Tf) and at 6(±30days) month follow-up procedure.
Variation between the final result of index PCI (Tf) and procedure at 6(±30days) month follow-up (Tc).
Time frame: immediately after the procedure and at 6(±30 days) months after the index PCI.
Target Lesion Revascularization (TLR)
Rate of target lesion revascularization (TLR) defined as urgent and non urgent
Time frame: During hospitalization and at 6(±30days) month follow-up.
Target Vessel Revascularization (TVR)
Rate of target vessel revascularization (TVR) defined as urgent and non-urgent.
Time frame: During hospitalization and at 6(±30days) month follow-up.
Target Vessel Failure (TVF)
Rate of target vessel failure, defined as cardiac death, target-vessel myocardial infarction and any target lesion revascularization.
Time frame: During hospitalization and at 6(±30days) month follow-up.
Individual components of the composite target vessel failure (TVF) endpoint (defined as cardiac death, target-vessel myocardial infarction and any target lesion revascularization)
Rate of the individual components of the composite target vessel failure (TVF) endpoint (defined as cardiac death, target-vessel myocardial infarction and any target lesion revascularization).
Time frame: During hospitalization and at 6(±30days) month follow-up.
Major adverse cardiac events (MACE) defined as cardiac death, any myocardial infarction and any revascularization.
Rate of major adverse cardiac events (MACE) defined as cardiac death, any myocardial infarction and any revascularization .
Time frame: 6(± 30 days) months after the index PCI.
The individual components of the composite major adverse cardiac events (MACE- defined as cardiac death, any myocardial infarction and any revascularization).
Rate of the individual components of the composite MACE endpoint (defined as cardiac death, any myocardial infarction, any revascularization).
Time frame: 6(± 30 days) months after the index PCI.
Stroke
Rate of stroke.
Time frame: 6(± 30 days) months after the index PCI.
Plan to share: No — The final study data will be disseminated to the scientific community through the publication of results in peer-reviewed journals, ensuring accessibility to researchers and healthcare professionals.
No publications or documents are linked to this record.
Start is estimated for Apr 2025; primary completion for Sep 2027, 29 months later.
Of 213 non-industry interventional studies with no phase under Acute Coronary Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 46. This study's planned 29 months is below that.
Counting every sponsor, half of 228 studies reached it within 34 months; a quarter within 17 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cardiocentro Ticino